Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies.

Rachele Cagliani, Francesca Magri, Antonio Toscano, Luciano Merlini, Francesco Fortunato, Costanza Lamperti, Carmelo Rodolico, Alessandro Prelle, Manuela Sironi, Mohammed Aguennouz, Patrizia Ciscato, Antonino Uncini, Maurizio Moggio, Nereo Bresolin, Giacomo P. Comi

Research output: Contribution to journalArticle

Abstract

Mutations in the DYSF gene underlie two main muscle diseases: Limb Girdle Muscular Dystrophy (LGMD) 2B and Miyoshi myopathy (MM). Dysferlin is involved in muscle membrane-repair and is thought to interact with other dysferlin molecules and annexins A1 and A2 at the sarcolemma. We performed genotype/phenotype correlations in a large cohort of dysferlinopathic patients and explored the possible role of annexins as modifier factors in LGMD-2B and MM. In particular, clinical examination, expression of sarcolemmal proteins and genetic analysis were performed on 27 dysferlinopathic subjects. Expression of A1 and A2 annexins was investigated in LGMD-2B/MM subjects and in patients with other muscle disorders. We identified 24 different DYSF mutations, 10 of them being novel. We observed no clear correlation between mutation type and clinical phenotype, but MM patients were found to display muscle symptoms significantly earlier in life than LGMD subjects. Remarkably, dysferlinopathic patients and subjects suffering from other muscular disorders expressed higher levels of both annexins compared to controls; a significant correlation was observed between annexin expression levels and clinical severity scores. Also, annexin amounts paralleled the degree of muscle histopathologic changes. In conclusion, our data indicate that the pathogenesis of different inherited and acquired muscle disorders involves annexin overexpression, probably because these proteins actively participate in the plasmalemma repair process. The positive correlation between annexin A1 and A2 and clinical severity, as well as muscle histopathology, suggests that their level may be a prognostic indicator of disease.

Original languageEnglish
Pages (from-to)283
Number of pages1
JournalHuman Mutation
Volume26
Issue number3
Publication statusPublished - Sep 2005

Fingerprint

Annexin A2
Annexin A1
Annexins
Muscular Dystrophies
Limb-Girdle Muscular Dystrophies
Muscles
Mutation
Muscular Diseases
Proteins
Sarcolemma
Genetic Association Studies
Phenotype
Membranes
Miyoshi myopathy
Genes

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. / Cagliani, Rachele; Magri, Francesca; Toscano, Antonio; Merlini, Luciano; Fortunato, Francesco; Lamperti, Costanza; Rodolico, Carmelo; Prelle, Alessandro; Sironi, Manuela; Aguennouz, Mohammed; Ciscato, Patrizia; Uncini, Antonino; Moggio, Maurizio; Bresolin, Nereo; Comi, Giacomo P.

In: Human Mutation, Vol. 26, No. 3, 09.2005, p. 283.

Research output: Contribution to journalArticle

Cagliani, Rachele ; Magri, Francesca ; Toscano, Antonio ; Merlini, Luciano ; Fortunato, Francesco ; Lamperti, Costanza ; Rodolico, Carmelo ; Prelle, Alessandro ; Sironi, Manuela ; Aguennouz, Mohammed ; Ciscato, Patrizia ; Uncini, Antonino ; Moggio, Maurizio ; Bresolin, Nereo ; Comi, Giacomo P. / Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. In: Human Mutation. 2005 ; Vol. 26, No. 3. pp. 283.
@article{0c36ad63a38041519011ea83052c4886,
title = "Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies.",
abstract = "Mutations in the DYSF gene underlie two main muscle diseases: Limb Girdle Muscular Dystrophy (LGMD) 2B and Miyoshi myopathy (MM). Dysferlin is involved in muscle membrane-repair and is thought to interact with other dysferlin molecules and annexins A1 and A2 at the sarcolemma. We performed genotype/phenotype correlations in a large cohort of dysferlinopathic patients and explored the possible role of annexins as modifier factors in LGMD-2B and MM. In particular, clinical examination, expression of sarcolemmal proteins and genetic analysis were performed on 27 dysferlinopathic subjects. Expression of A1 and A2 annexins was investigated in LGMD-2B/MM subjects and in patients with other muscle disorders. We identified 24 different DYSF mutations, 10 of them being novel. We observed no clear correlation between mutation type and clinical phenotype, but MM patients were found to display muscle symptoms significantly earlier in life than LGMD subjects. Remarkably, dysferlinopathic patients and subjects suffering from other muscular disorders expressed higher levels of both annexins compared to controls; a significant correlation was observed between annexin expression levels and clinical severity scores. Also, annexin amounts paralleled the degree of muscle histopathologic changes. In conclusion, our data indicate that the pathogenesis of different inherited and acquired muscle disorders involves annexin overexpression, probably because these proteins actively participate in the plasmalemma repair process. The positive correlation between annexin A1 and A2 and clinical severity, as well as muscle histopathology, suggests that their level may be a prognostic indicator of disease.",
author = "Rachele Cagliani and Francesca Magri and Antonio Toscano and Luciano Merlini and Francesco Fortunato and Costanza Lamperti and Carmelo Rodolico and Alessandro Prelle and Manuela Sironi and Mohammed Aguennouz and Patrizia Ciscato and Antonino Uncini and Maurizio Moggio and Nereo Bresolin and Comi, {Giacomo P.}",
year = "2005",
month = "9",
language = "English",
volume = "26",
pages = "283",
journal = "Human Mutation",
issn = "1059-7794",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies.

AU - Cagliani, Rachele

AU - Magri, Francesca

AU - Toscano, Antonio

AU - Merlini, Luciano

AU - Fortunato, Francesco

AU - Lamperti, Costanza

AU - Rodolico, Carmelo

AU - Prelle, Alessandro

AU - Sironi, Manuela

AU - Aguennouz, Mohammed

AU - Ciscato, Patrizia

AU - Uncini, Antonino

AU - Moggio, Maurizio

AU - Bresolin, Nereo

AU - Comi, Giacomo P.

PY - 2005/9

Y1 - 2005/9

N2 - Mutations in the DYSF gene underlie two main muscle diseases: Limb Girdle Muscular Dystrophy (LGMD) 2B and Miyoshi myopathy (MM). Dysferlin is involved in muscle membrane-repair and is thought to interact with other dysferlin molecules and annexins A1 and A2 at the sarcolemma. We performed genotype/phenotype correlations in a large cohort of dysferlinopathic patients and explored the possible role of annexins as modifier factors in LGMD-2B and MM. In particular, clinical examination, expression of sarcolemmal proteins and genetic analysis were performed on 27 dysferlinopathic subjects. Expression of A1 and A2 annexins was investigated in LGMD-2B/MM subjects and in patients with other muscle disorders. We identified 24 different DYSF mutations, 10 of them being novel. We observed no clear correlation between mutation type and clinical phenotype, but MM patients were found to display muscle symptoms significantly earlier in life than LGMD subjects. Remarkably, dysferlinopathic patients and subjects suffering from other muscular disorders expressed higher levels of both annexins compared to controls; a significant correlation was observed between annexin expression levels and clinical severity scores. Also, annexin amounts paralleled the degree of muscle histopathologic changes. In conclusion, our data indicate that the pathogenesis of different inherited and acquired muscle disorders involves annexin overexpression, probably because these proteins actively participate in the plasmalemma repair process. The positive correlation between annexin A1 and A2 and clinical severity, as well as muscle histopathology, suggests that their level may be a prognostic indicator of disease.

AB - Mutations in the DYSF gene underlie two main muscle diseases: Limb Girdle Muscular Dystrophy (LGMD) 2B and Miyoshi myopathy (MM). Dysferlin is involved in muscle membrane-repair and is thought to interact with other dysferlin molecules and annexins A1 and A2 at the sarcolemma. We performed genotype/phenotype correlations in a large cohort of dysferlinopathic patients and explored the possible role of annexins as modifier factors in LGMD-2B and MM. In particular, clinical examination, expression of sarcolemmal proteins and genetic analysis were performed on 27 dysferlinopathic subjects. Expression of A1 and A2 annexins was investigated in LGMD-2B/MM subjects and in patients with other muscle disorders. We identified 24 different DYSF mutations, 10 of them being novel. We observed no clear correlation between mutation type and clinical phenotype, but MM patients were found to display muscle symptoms significantly earlier in life than LGMD subjects. Remarkably, dysferlinopathic patients and subjects suffering from other muscular disorders expressed higher levels of both annexins compared to controls; a significant correlation was observed between annexin expression levels and clinical severity scores. Also, annexin amounts paralleled the degree of muscle histopathologic changes. In conclusion, our data indicate that the pathogenesis of different inherited and acquired muscle disorders involves annexin overexpression, probably because these proteins actively participate in the plasmalemma repair process. The positive correlation between annexin A1 and A2 and clinical severity, as well as muscle histopathology, suggests that their level may be a prognostic indicator of disease.

UR - http://www.scopus.com/inward/record.url?scp=33746701373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746701373&partnerID=8YFLogxK

M3 - Article

C2 - 16100712

AN - SCOPUS:33746701373

VL - 26

SP - 283

JO - Human Mutation

JF - Human Mutation

SN - 1059-7794

IS - 3

ER -